The 2026 Congress marks a significant evolution for AEON, transitioning from an intensive medical masterclass into a full-scale international platform. The event is set to convene a prestigious ...

Thomas Rantzau, employee representative on the Board of Directors since 2018, has decided to pursue new opportunities outside Novo Nordisk A/S after 22 years of employment. Therefore, he steps down ...

Kyowa Kirin reprend le contrôle du programme de développement et de commercialisation du rocatinlimab, manifestant ainsi son profond engagement visant à répondre aux besoins médicaux non satisfaits ...

After sustaining water damage during the massive November 2025 fire at Keswick Castle in Hampden, The Womb Room, a Baltimore-based perinatal wellness center, has officially resumed in-person ...

LOS ANGELES, Jan. 30, 2026 (GLOBE NEWSWIRE) -- As part of Grammy Week in Los Angeles, Oxford Healthspan will offer a preview of its new Primeadine® GF Powder on February 1, through a custom Primeadine ...

Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“Enzon” or the “Company”), today announced that it has commenced an exchange offer (the “Offer”) involving its Series C Non-Convertible Redeemable Preferred ...

MINNEAPOLIS, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Park Dental Partners, Inc. (NASDAQ: PARK), a leading dental resource organization, today announced that it will report its financial results for the ...

Since joining Olema in 2020, Shane has been a valuable member of our team, helping to lead and grow the Company as we have progressed palazestrant through late-stage clinical development and expanded ...

The accepted paper, titled "Evaluation of Urcosimod in Neuropathic Corneal Pain: Efficacy and Safety Results from a Proof-of-Concept Pilot Phase 2 Study", will be presented in the Ocular Surface ...

The Company believes Mr. Gabbai’s experience in healthcare leadership, capital markets, and with global investors will be valuable as NurExone advances its preclinical programs toward first-in-human ...

- Exploratory analysis from Phase 1b/2 breast cancer trial reinforces CD47 as a predictive biomarker for response, as previously observed in the ASPEN-06 trial in HER2-positive gastric cancer – ...

Tevogen Bio, the company’s lead initiative, has completed a proof-of-concept clinical trial demonstrating the potential of its single-HLA-restricted, genetically unmodified allogeneic T cells. Tevogen ...